Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (up 149.0% year over year) with net income of −$37M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- +149.0% YoY · −45.4% QoQ
- Net income
- −$37M
- +38.1% YoY · +70.9% QoQ
- Operating margin
- -1666.3%
- EPS (diluted)
- −$0.68
- +38.2% YoY · +70.8% QoQ
Source: XBRL data from the PROTHENA CORP PUBLIC LTD CO (PRTA) Q3 2025 10-Q on SEC EDGAR. USD.
PROTHENA CORP PUBLIC LTD CO Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Contractual obligations $30.85M, including restructuring $17.614M and operating leases $9.932M
- 2025 contractual payments $20.646M, including restructuring obligations $16.776M
- Brisbane sublease obligations $14.9M, with $9.7M outstanding at September 30, 2025
- Full-year 2025 operating and investing cash use expected at approximately $170M–$178M
Risk Factors
- Net losses $222.5 million and accumulated deficit $1.3 billion as of September 30, 2025
- Cash and equivalents $330.8 million, with balances potentially exceeding $250,000 FDIC insurance limits
- Clinical-development disruption risk from winding down PRX012 and birtamimab trials while supporting PRX019
- Privacy-compliance exposure under EU GDPR, including fines up to €20 million or 4% of global annual turnover
- Cybersecurity breach risk affecting clinical-trial data and regulatory approval timelines
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROTHENA CORP PUBLIC LTD CO quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.